Abiomed (ABMD) Tops Q2 EPS by 6c

Abiomed (NASDAQ: ABMD) reported Q2 EPS of $1.03, $0.06 better than the analyst estimate of $0.97. Revenue for the quarter came in at $248.1 million versus the consensus estimate of $247.66 million.

GUIDANCE:

Abiomed sees FY2022 revenue of $1.01-1.03 billion, versus the consensus of $1.04 billion.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
• AXIL Brands (AXIL) Tops Q4 EPS by 4c